You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Asthma medicines evidence packs

These asthma evidence summary packs provide licensing information, clinical, financial and environmental data to support payers/commissioners and healthcare professionals to make a formulary application and /or decide positioning within a local guideline.

Relvar Ellipta asthma evidence summary

Download PDF

Relvar Ellipta asthma evidence dossier

Download PDF

COPD medicines evidence packs

These COPD evidence summary packs provide licensing information, clinical, financial and environmental data to support payers/commissioners and healthcare professionals to make a formulary application and /or decide positioning within a local guideline.

Relvar Ellipta COPD evidence summary

Download PDF

Trelegy Ellipta COPD evidence summary

Learn more

Incruse Ellipta COPD evidence summary

Download PDF

Anoro Ellipta COPD evidence summary

Download PDF

Chat on-demand with a health outcomes consultant

Explore the cost of the Ellipta portfolio and contact us to find out how this could impact your local prescribing.

ANORO ELLIPTA and RELVAR ELLIPTA were developed in collaboration with

Innoviva logo

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Anoro, Incruse, Relvar, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies 

I.H. Last updated: January 2018. UK/RESP/0486/15(5)